CN Patent

CN101641352A — 取代的4-芳基-1,4-二氢-1,6-萘啶酰胺和其用途

Assigned to Bayer Intellectual Property GmbH · Expires 2010-02-03 · 16y expired

What this patent protects

本申请涉及新的被取代的4－芳基－1，4－二氢－1，6－萘啶－3－羧酰胺，其制备方法，其用于治疗和/或预防疾病的用途，和其用于制备用以治疗和/或预防疾病，特别是心血管病症的药物的用途。

USPTO Abstract

本申请涉及新的被取代的4－芳基－1，4－二氢－1，6－萘啶－3－羧酰胺，其制备方法，其用于治疗和/或预防疾病的用途，和其用于制备用以治疗和/或预防疾病，特别是心血管病症的药物的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN101641352A
Jurisdiction
CN
Classification
—
Expires
2010-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Intellectual Property GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.